{
    "symbol": "PBYI",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-02 18:29:08",
    "content": " Today, Puma reported total revenue for the fourth quarter of 2022 of $65.7 million. Product revenue net was $53.7 million in the fourth quarter of 2022, compared to $54.3 million reported in Q3 2022 and $51.0 million reported in Q4 of 2021. Royalty revenue was $12 million in the fourth quarter of 2022, an increase from $2.8 million in Q3 of 2022 and an increase from $2.9 million in Q4 of 2021. Biomarker data from the randomized trial of alisertib plus paclitaxel versus paclitaxel alone in hormone receptor positive HER2-negative breast cancer, anticipated in the first half of '23, data from the ongoing investigator-sponsored Phase 1/2 trial of alisertib plus pembro for the treatment of patients with Rb-deficient head and neck squamous cell cancer, which is anticipated sometime in '23. As Alan noted, our net product sales were $53.7 million in the fourth quarter of 2022. In Q4, we estimate that inventory increased by approximately $2.6 million in the fourth quarter of 2022. In the fourth quarter of 2022, we reported a net loss based on GAAP of $5.6 million or $0.12 per share. On a non-GAAP basis, which is included to remove the impact of stock-based compensation expense, we reported a net loss of $3 million or $0.07 per share for the fourth quarter 2022. As Alan mentioned, net product revenue from NERLYNX sales was $53.7 million compared to the $54.3 million reported in the third quarter of '22. The fourth quarter of 2022, Puma reported cash earned of approximately $3.1 million compared to cash earned of approximately $17.4 million in Q3 2022."
}